NICE
-
NHS rolls out first targeted anal cancer drug, extending survival to nearly three years
Retifanlimab plus chemotherapy adds 10 months of life for 250 patients annually in England, available immediately.
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
NHS rolls out first targeted anal cancer drug, extending survival to nearly three years
-
How the OncoMate MSI Dx Test Guides Pembrolizumab Therapy
-
NIH Study Links Forever Chemicals to Aggressive Breast Cancer Rates
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992